Niagen Bioscience Expands Access with Telehealth Platform and At-Home Injection Kit
Event summary
- Niagen Bioscience launched a clinician-directed telehealth platform, Niagen Plus, enabling U.S. patients to access prescription-only Niagen At-Home Injection Kits.
- The platform guides patients through an online medical intake and consultation with a licensed provider before prescribing the injection kit.
- The Niagen At-Home Injection Kit includes a sterile 500 mg vial of Niagen powder, bacteriostatic water, injection syringes, and step-by-step instructions.
- The U.S. injectable industry was valued at USD 223.6 billion in 2025, with projected growth at 6.8% CAGR through 2035.
- The longevity market is projected to grow from USD 9.16 billion in 2025 to USD 20.17 billion by 2035, a CAGR of 8.34%.
The big picture
Niagen Bioscience's launch of the Niagen Plus telehealth platform and at-home injection kit represents a strategic move to expand access to its pharmaceutical-grade NAD+ products. This initiative aligns with broader industry trends towards telehealth and at-home healthcare solutions, particularly in the growing longevity and injectable markets. The company's focus on clinician-directed oversight and quality standards positions it to compete in a rapidly evolving healthcare landscape.
What we're watching
- Market Penetration
- Whether Niagen Bioscience can effectively scale its telehealth platform to capture a significant share of the growing longevity and injectable markets.
- Regulatory Compliance
- How the company will navigate regulatory requirements for telehealth and at-home injection kits, ensuring compliance with FDA standards.
- Competitive Dynamics
- The pace at which competitors in the NAD+ and healthy aging space introduce similar telehealth and at-home solutions.
Related topics